Plasmid Encoding P62/Sqstm1 Administered In Combination With Cmf Chemotherapy Improves Outcomes In Metastatic Triple-Negative Breast Cancer Patients

CMF (Cyclophosphamide 600mg/m2 + Methotrexate 40mg/m2 + Fluorouracil 600mg/m2, IV, day 1 and 8, every 4 weeks) remains a chemotherapeutic modality effective for metastatic triple-negative breast cancer (mTNBC). A plasmid encoding p62/SQTM1 reduces chronic inflammation, changes the tumor microenvironment, and increases the number of tumor-infiltrating lymphocytes. Dosing of the plasmid preserved the lives of 10 out of 11 dogs with breast cancer. In a human phase I/IIa trial, it demonstrated an excellent safety profile and limited cancer progression.